The article has been automatically translated into English by Google Translate from Russian and has not been edited.
Переклад цього матеріалу українською мовою з російської було автоматично здійснено сервісом Google Translate, без подальшого редагування тексту.
Bu məqalə Google Translate servisi vasitəsi ilə avtomatik olaraq rus dilindən azərbaycan dilinə tərcümə olunmuşdur. Bundan sonra mətn redaktə edilməmişdir.

Reduces the concentration of the virus: a cheap drug for cholesterol cures for COVID-19

A recent study found that a drug designed to treat high cholesterol levels also lowers the risk of contracting COVID-19 by 70% and reduces its spread from one person to another. He writes about it Fox8.

Photo: Shutterstock

A team of researchers led by the University of Birmingham and Keele University in the UK and the San Raffaele Institute of Science in Italy tested the oral drug fenofibrate and its active form, fenofibric acid, against SARS-COV-2 and found that it reduces the risk of human infection.

Fenofibrate, approved for use in most countries around the world, including the US Food and Drug Administration (FDA) and the UK's National Institutes of Health and Medical Services, is currently used to treat conditions such as high cholesterol and abnormal levels fatty substances, or lipids in the blood.

SARS-CoV-2, the virus that causes COVID-19, infects the host through an interaction between the Spike protein on the surface of the virus and the ACE2 receptor protein on the host cells.

On the subject: How long does immunity last after vaccination against COVID-19: data on different drugs

In response to the global pandemic, the team began testing a group of already licensed drugs, including fenofibrate, to see if any of them interfered with the interactions between ACE2 and Spike.

Finding that fenofibrate successfully disrupts interactions, they then tested the effect of the drug on human cells infected with the original strains of the SARS-CoV-2 virus isolated in 2020.

According to the report, they found that fenofibrate reduced infection by up to 70%.

Co-author Dr. Eliza Vicenzi of the San Raffaele Science Institute in Milan, Italy said: “Our data shows that fenofibrate may have the potential to reduce the severity of COVID-19 symptoms as well as the spread of the virus. Given that fenofibrate is an oral drug that is very cheap and available globally, together with its extensive clinical history and good safety profile, our data are of global importance, especially in low-middle-income countries and those for whom vaccination is not recommended. "

You may be interested in: top New York news, stories of our immigrants and helpful tips about life in the Big Apple - read it all on ForumDaily New York.

The release also says additional unpublished data show that fenofibrate is equally effective against newer SARS-CoV-2 variants, including alpha and beta variants. Research is ongoing to reduce it for delta-variant infections.

The team is now calling for clinical trials of the drug in hospitalized patients with COVID-19.

Read also on ForumDaily:

How long does immunity last after vaccination against COVID-19: data on different drugs

Covid discoveries: what we know now about the coronavirus that we did not know before

Covidiot and coronicles: 7 new words that emerged during the pandemic

No need to carry a vaccination card: how to prove with a smartphone that you are vaccinated against COVID-19

Stroke is 'getting younger': how you can reduce your risk of cerebral hemorrhage

Educational program Special Projects COVID-19
Subscribe to ForumDaily on Google News

Do you want more important and interesting news about life in the USA and immigration to America? Subscribe to our page in Facebook. Choose the "Display Priority" option and read us first. Also, don't forget to subscribe to our РєР ° РЅР ° Р »РІ Telegram - there are many interesting things. And join thousands of readers ForumDaily Woman и ForumDaily New York - there you will find a lot of interesting and positive information. 

1158 requests in 2,361 seconds.